One of the places that I find stocks to blog about is on Google Finance.  On the first page is a listing of the stocks that are “in the news”.  These are the stocks that are getting the most searches or maybe are a leader in volume, price change or some other measure.  One penny stock that caught my eye was:

Newport Digital Technologies, Inc.  (NPDT)

NPDT, for the purposes of this blog, is primarily a chart play.  The company has yet to generate revenues, but from the PR’s it sure sounds like they are the  next Microsoft (jk).   They are a technology company allied with incubators in Taiwan and are creating products to match their competencies in WIMAX, RFID, Digital Signage, VOIP  and Security and Surveillance.  The technology is very interesting and has the potential to be HUGE.  Personally, I would like to see more PR’s touting sales, sales commitments, contracts, etc….

But, as a chart play, it might make sense.

I actually like the technology behind what NPDT is offering.  It recently announced that A WIMAX/RFID Alpha site is being brought online with a medical complex in Newport Beach, CA.  I will watch with interest to see how that goes and if it can be a springboard to other projects.  In the RFID arena, their goal is to replace bar codes and bar coding.

Here are some sites for your own due diligence:

Yahoo! Finance link

Company website

Good luck and good trading,

Jeffrey Dean

Editor-in-Chief

——————————————————————————————————————————————-

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Sirius XM Radio (SIRI) has made an almost miraculous comeback from irrelevancy (and penny stock land) over the past few months.  SIRI has seen its stock rise from the low $.50’s at the end of 2009 to a recent high of around $1.15 just a few days ago.  This was very good news for the company.  Since it was facing a NASDAQ delisting and with the stock trading above the magic $1.00 mark for a period of time, SIRI was thinking it was “scot-free”.  Think again.

Last week’s drop (and this week’s continuing drop) was not surprising given the overheated condition of the stock from all indicators.  It is not clear what effect short sellers had in the decline since the short squeeze had been on for many months with the advance of the stock price.  SIRI fought through all of those challenges….that is until now.

SIRI has one more chance to regain compliance with NASDAQ regs if it can trade above $1.00 for 10 consecutive days before the March 15th date imposed by the exchange.  I don’t see that happening.  The reverse split that has been discussed seems the only option now despite management’s contention that they will be able to get a variance on appeal.  NOT BLOODY LIKELY.

SIRI should have executed the reverse split when they were so strong late last year.  The market was really pumped on SIRI and its progress.  Institutions were buying and retail investors were very happy with the run-up.  Now with a delisting notice sure to come, short sellers will be circling SIRI like sharks looking for blood.  I think the short term outlook for SIRI is definitely bearish.

Here is a chart that shows what I mean.

Is SIRI a dead dog?  Will shorters drive this one right back down to 50 cents (or lower) again.  I don’t think so.  SIRI is in a “stew of its own making”, but I think will be a good stock to buy on dips.  Right now, I would hold off (unless you are shorting the stock).  The boards and investor sentiment are telling me that this one has farther to fall.  Retail investors might not like it when they do the reverse stock split, but IMO it is inevitable.

Do your own due diligence.  It continues to be a hot topic on the boards that I monitor and it is fun to read what people write.  Make up your own mind.

Good luck and good trading,

Jeffrey Dean

Editor-in-Chief

—————————————————————————————————————————————————

<!– /* Font Definitions */ @font-face {font-family:”Cambria Math”; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-1610611985 1107304683 0 0 159 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-1610611985 1073741899 0 0 159 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:”"; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:”Times New Roman”,”serif”; mso-fareast-font-family:”Times New Roman”;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:10.0pt; mso-ansi-font-size:10.0pt; mso-bidi-font-size:10.0pt;} @page Section1 {size:8.5in 11.0in; margin:1.0in 1.25in 1.0in 1.25in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.Section1 {page:Section1;} –>

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

First a personal update:  Friday’s blog was kind of “doom and gloom” when I was stuck in the middle of a power outage (second year in a row for NH).  Even thought I got power back relatively quickly, I am still shopping online for an emergency generator.  Family is fine, house is safe and my section of NH is no longer a third-world country.  It is amazing how we take important things (like power) for granted.

Now…on to stocks.

My scans today produced NightHawk Radiology Holdings, Inc. (NHWK). Nighthawk is at the end of a prolonged decline in its stock price IMO.  This might be a good time to put it on the radar.  If it recovers from its February swoon and embarks on a climb like last year, you will like me very, very much.

Here is what I am talking about (1 yr. chart for NHWK)

NHWK is actually a very impressive company.  They have a dominant market position in their industry.  They provide services to radiology groups and hospitals throughout the United States.  NHWK provides a complete suite of solutions to doctors and hospitals, including professional services, business services, and its advanced, proprietary clinical workflow technology.  The company claims to provide round-the-clock services for for approximately 1,560 sites or 27% of all hospitals in the United States.   That is pretty impressive!

What is also impressive is that they make money.  Revenues of $162 million in ‘09, but a loss in 2009 due to a $68.7MM  goodwill impairment charge (so, I wouldn’t hold it against them).  L-T debt of $77MM, but great liquidity ratios.  Plenty of cash in the bank ($32.29MM) and over $1.37 in cash per share.

Here is the 3 month chart so traders can see in greater detail what is going on.

Here is my final analysis.  The table below is a chart of NHWK’s highs and lows during the last year.  Lots of volatility and nice bounces off lows to post highs again.  A trader could make a great profit of trading these swings.

Do you see why I say that this is a great radar stock?

I will be watching it myself.

Good luck and good trading,

Jeffrey Dean

Editor

I must apologize first for not blogging on Monday and Tuesday, but I was on a ski trip with the family and not thinking about the markets.  My alert for Monday (BLGW) is doing very well I’m happy to report.

I jumped back in to my research this morning and came across a great company that has solid prospects:  Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis:physiological process involving the growth of new blood vessels from pre-existing vessels).

GTF’s AutoloGel System utilizes a unique technology that enables rapid isolation and activation of platelet rich plasma (PRP) from a patient’s own blood. The PRP is subsequently processed to produce a gel for application to the wound bed, re-establishing a balance needed for natural healing to occur. AutoloGel contains growth factors, cytokines and chemokines that are essential for normal wound healing. The AutoloGel System is used at the point-of care and is the only PRP System indicated for use in exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically-debrided wounds.  The AutoloGel System is the only PRP system that is FDA cleared for the care of wounds.

The company is generating revenues and those revenues are increasing significantly.  They have cash-in-the-bank and NO long term debt….always a positive sign for me.  With the 2009 capital raise, that bought the company some time to execute on their plan.  Based upon what I have seen, they have high expectations for their AutoloGel System.

The chart indicates that the stock is trading near the bottom of its most recent trading range.

• After a steep selloff, the stock might be ready to run again
• An Amex stock, GTF is trading at attractive levels
• The strongest support is at 40 cents (see the chart)…. I don’t think it will drop that far, but it could
  

I am recommending that traders put GTF on their radar screens.  I think the downside risk is low, but the upside is strong.

As always, do your own due diligence.

Good luck and good trading,

Jeffrey Dean

Editor

The last time I blogged Coates International, Ltd. (COTE) was to tell traders to short them (Read it here).  And, I was right.  I liked the company  fundamentally, but thought that the chart was setting it up for a fall.  COTE blazed a trail across the markets back in July of ‘09 almost tripling in value from around 40 cents to $1.15.  In my earlier blog, I said the following:  “The stock might be due for a correction in the near future.  Any kind of reasonable “support” for the stock is around the 50 cent mark….so, it could fall a long way!”

Three days later, the stock was at 53 cents! A penny stock, once again!

Now, the chart is turned around.  The stock price is depressed and I think that COTE should be watched for a bounce in the near term (and it could be the next hot stock if they start landing some contracts).

Let’s talk about the company:  COTE is the creator, developer and manufacturer of the patented Coates spherical rotary valve system (CSRV System) for use in various piston-driven internal combustion engines.  It is a technology that has been under development for over 15 years and may now be “ready for its closeup”.  The company is claiming that they have created the internal combustion engine of the future.  They claim significant benefits compared to the engines of today: Increased Engine Efficiency, Lower Emissions, Reduced Lubrication Requirements, Cheaper to Manufacture, and Adaptable to Multiple Fuel Types.  Here is a link to a very informative article done on COTE by Industry Online.  I am not an automotive engineer, but it sounds like COTE has something in their CSRV technology.

With the income of a Canadian sale for $10MM ($8 MM of which remains a receivable), its Chinese manufacturing initiatives and several Beta sites that are under negotiation, it might be a good time to put COTE on your trading radar.

The chart looks good for gains!

• COTE is trading near its 52-week low ($0.28);
• Watch to see if this level acts as support for the stock…any break below 32 cents should be watched to see if a new bottom develops;
• The MACD is drifting….with good news and some buying, it could turn bullish very quickly.

Another factor to consider about COTE that gives me comfort is the insider ownership.  I like the fact that insiders own over 80% of the company.  COTE hasn’t been an overnight sensation.  My impression is that they have a core group of founders and executives that believe in the mission of the company and are in for the long haul.  I hope they get rewarded, because that means I will be rewarded too.  I have put COTE on my own personal trading radar with the idea of buying shares in the very near future.  I have a call in to the company and will update my blog with any intelligence I gather.

Do your due diligence!

Good luck and good trading,

Jeffrey Dean

Editor-in-Chief

********************************************************************************************

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

I got an email yesterday  from one of my members (Jeff D.) asking me my opinion on what happened to Labopharm, Inc. (DDSS).  Jeff was at a loss to explain why DDSS’ shares dropped so preciptiously after getting FDA approval on one of their signature drugs.  In some ways, so am I.

Headlines like this one:

Labopharm Receives FDA Approval For OLEPTRO(TM)

usually means that a drug stock will rocket upwards.  Not in DDSS’ case.  The stock lost 40% of its value in just a few days.   Read full release here

You can see from the chart here just what I am talking about:

Stocks dropping on news of approvals is not uncommon ( see BDSI, NRIFF, PK and others), but it is still unexpected.   DDSS, the company, actually has a lot going for it.  It has income (no profits), cash in the bank, good ratios, manageable debt….and a big payday coming some time this year.  I have read where DDSS is in talks with several larger pharmaceutical firms regarding the commercialization of their newest drug, Oleptro.  I can only imagine the frenzy at DDSS offices as they take this surprise announcement and try and turn it into revenues.

I am not terribly surprised at the drop given the rise in the share price in anticipation of approval.  And, I am betting that DDSS will come back and come back strong.  Since I am a technical analyst, I will share one last chart with readers that backs up my contention.

This chart shows how volatile the stock has been and I think it is illustrative of the recuperative powers of DDSS.  You can see that the stock is trading within normal ranges and has shown great historical elasticity.  I would not be too worried about this dip and, in fact, would see this as a buying opportunity.  Having said that, there is support at $1.75 and $1.40.  I don’t think it will drop to those levels, but…you never know.

DDSS is both a short-term and a long-term hold.  In the short-term, I could see the stock regaining much of its recent losses.  It certainly seems like the sellers are out.  In the long-term, DDSS could be a “gold mine”.  I will watch with great interest for news on how they will commercialize this and what the financial ramifications are for the company.

I didn’t spend any time in this blog on drug pipelines and other pharma standards.  I expect that my readers will do their own DD.  Here is DDSS’s website link for your own research.

Trade like you mean it!

Jeffrey Dean

Editor-in-Chief

Note on 2/12/10:  DDSS is getting hammered.  The market did not like the news of their $20MM  offering.   DDSS blew through the $1.75 support and is headed down to the $1.40 level.  MIght be best to take an EVEN more cautious approach to this one.

Today’s alert company Biopack Environmental Solutions Inc. (BPAC) is a second look for many Soup members.  I previewed this stock with members in early 2010 and, in a multi-day move, returned a solid 42% gain.

It was one of the easiest moves I have watched in a long time. The chart is setting up nice right now, and I am hoping that we are all in for another nice ride. continue

Carbon Dioxide (CO2) has gotten a bad rap for causing pollution, the greenhouse effect AND global warming.  Deservedly so, in most cases.

Fossil fuels such as oil, gas and coal have powered the world’s economic growth since the days of the industrial revolution.   As the world economies expand, so does the need for fossil fuels.  The U.S. Energy Information Administration projects that global energy consumption will increase 50% by 2030 to over 112 million barrels of crude oil per day.  The economic cost is significant with the price of oil and coal setting new highs seemingly every day, but the environmental impact is staggering with BILLIONS of tons of CO2 into the atmosphere annually.

What if there was a way to turn that pollution into profits?

Yes!  That is what today’s alert company Carbon Sciences, Inc. (CABN) is doing! continue

I was tempted to have a title that said something like “Helix Wind…that company really blows”, but I thought better of it. That wouldn’t be too professional.  I am serious, however, when I say that my readers should take a look at the company.

Helix Wind Corporation (HLXW) is engaged in the design, manufacturing and sale of “small wind” vertical axis turbines (VAWT) designed to generate clean, renewable electricity from wind.  The key for HLXW is the term “small wind”.   The company makes its case for the small wind strategy on its site:

“Small (or “residential”) wind energy systems typically generate just enough power to meet the demands of a home, farm or small business. They range from 400 watts to 500 kilowatts or more and typically consist of a single turbine (vertical or horizontal). They can be significant power sources and have proven records of performance, even in locations with modest winds.”

Here is graphic evidence on how they are different:

This is not the typical propeller blade turbine that is used on the wind farm installations that are so popular these days. This is a uniquely designed, niche product that is scalable from a single residence (the S322) to the D15000 which produces enough electricity for 10 homes or a medium size commercial facility.   Helix believes that the VAWT configuration is superior due to the fact that functions in wind that comes from all directions and is well suited to gusty wind conditions which typical blade wind turbines are not.

Here is a link to HLXW’s website. It is a very well done site and has a great deal of interesting information on it.  They also have a Fact Sheet nested on their site that makes for good reading.

Now, lets talk about the company and the chart. The company is long on promise and good news, but short on cash.  While the company is booking revenues, it is losing millions of $ every quarter.  The Balance Sheet is no help.  The company is essentially insolvent according to their last quarterly statement.  I have confirmed that the company is raising capital and is actually in a “quiet period” before the announcement which could happen as early as next month.  The key shareholders are subject to a lock-up of their shares in conjunction with the capital raise.

The company has released info on potential orders, but it is sparse.  The Argentinian deal sounds good for the company, but near term it doesn’t appear to help too much.  I would like to see more press releases about sales and distribution.   The company has not issued revenue guidance for 2010 yet, but says they plan to later in the year once the financing is wrapped up and at least one more acquisition is closed.

The chart makes for interesting study:

HLXW is a company worth watching. The stock may have farther to fall based upon momentum and trend lines.  In their industry, there is no market leader in the small wind category.  HLXW wants to become that market leader and in my conversations with the company, they feel that it can be achieved.   Certainly, government and utility subsidies and credits will continue to help drive wind power forward.   But, HLXW has to achieve their financing goals first before “world domination” is possible.

Honestly, I have fallen in love with the product and think that, on its face, it makes a great deal of sense for the market.  If the company wants to install a Helix wind turbine on my house, I will love them even more.

Good luck and good trading,

Jeffrey Dean

Editor

****************************************************************************************************

RGEN posted a 52-week low on Friday and appears to be losing the hearts and minds of investors.  Could be a good time to invest!

Repligen Corporation (RGEN) is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.  It is unique in the world of biopharma for several reasons…it has significant income already and it is sitting on a huge amount of cash.  Biopharma companies are traditionally very volatile.  Well, the pendulum for RGEN has been swinging the wrong way for quite a while.  I would not be surprised to see that pendulum swing back.

The news that “drove a stake in theheart” of RGEN’s stock price was the news that one of their drugs, a pancreas imaging agent designated RG1068, did not meet its main goal in a late-stage clinical study.  In an overreaction typical of the biopharma space, the stock tanked.  While the company tried to put a positive spin on it, it was clear that the drug has problems.  According to the company, they will determine the drug’s future after discussions with the FDA in early 2010.

What this news overshadowed, in my mind, is that RGEN is SO MUCH MORE than just this one drug.  Fiscal year end 2008 and 2009 (March 31st) showed a profit for the full year.  While the company is operating at a Quarter-over-Quarter loss this year, the company is on a run rate to book revenues of over $20MM.  The company has an absolutely ROCK SOLID balance sheet….cash and equivalents of over $42MM and NO LONG TERM DEBT.

RGEN’s recent news hasn’t been all bad either. Shortly after the RG1068 announcement, RGEN ann0unced the the Muscular Dystrophy Association (MDA) awarded them a grant for $731,000 for further research into new treatments for Friedreich’s ataxia.  This grant will support the completion of preclinical GLP toxicology testing and GMP manufacture of a drug candidate for human clinical trials.  The company believes that this funding is significant because it is evidence of support from the MDA not only provides important funding for Repligen’s research but it also provides access to a global network of scientists, physicians and patients.  This is the second research grant that RGEN has received from the MDA to support its Friedreich’s ataxia program.

To the Chart!

Clearly, RGEN is on a negative trend and no one call a bottom.  However, the stock bears watching.  It has the kind of balance sheet, revenue stream, position in the industry that makes me believe that this dip in stock price could only be temporary.  It has heavy insider and institution ownership, the short percentage is under 5% and is sitting on lots of cash.

Radar RGEN.…any good news will easily recover the lost value in the shares and the company has the financial wherewithal to “stay in the game” for a long, long time.

Good luck and good trading,

Jeffrey Dean, Editor

*******************************************************************************************************

<!– /* Font Definitions */ @font-face {font-family:”Cambria Math”; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-1610611985 1107304683 0 0 159 0;} @font-face {font-family:Verdana; panose-1:2 11 6 4 3 5 4 4 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:536871559 0 0 0 415 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:”"; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:”Times New Roman”,”serif”; mso-fareast-font-family:”Times New Roman”;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:10.0pt; mso-ansi-font-size:10.0pt; mso-bidi-font-size:10.0pt;} @page Section1 {size:8.5in 11.0in; margin:1.0in 1.25in 1.0in 1.25in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.Section1 {page:Section1;} –>

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Neither InvestorSoup.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.